Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| King's College London | OTHER |
| University of Glasgow | OTHER |
| Cornell University | OTHER |
| Queen Mary University of London |
Not provided
Not provided
Not provided
Not provided
The project aims to establish a database of cardiovascular patients using HES and linked mortality data. This database will be used to model trials in silico with the aim of informing the design of future cardiovascular trials in the United Kingdom.
Routinely collected health data such as National Health Service Hospital Episode Statistics (HES) contains a wealth of real-world longitudinal patient health data including demographics, diagnoses, procedures and other clinical information. These data can be used to address many of the existing challenges in the design and conduct of clinical trials by optimising trial design and simplifying the assessment of adherence, safety, and outcomes. When a trial concept is initiated, researchers may use HES data to explore the hypothesis and assess trial feasibility. The large-volume patient data enables a detailed understanding of the characteristics of the target patient populations and the estimation of the real-world treatment effects across different patient groups thus enabling identification of targeted populations for specific interventions. By tapping into this resource and using advanced statistical and machine learning methods, the investigators can emulate the trial and thus obtain the key trial parameters required for designing a clinical trial, minimise the number of assumptions imputed and make the design and development of clinical trials quicker, simpler, and more reliable.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard of Care | As recommended by treatment guidelines. | ||
| Cardiovascular Intervention | Examples include:
|
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Major adverse cardiovascular events (MACE) and their components | As specified in the trial protocol | 1-Year |
| Major adverse cardiovascular events (MACE) and their components | As specified in the trial protocol | 3-Year |
| Major adverse cardiovascular events (MACE) and their components | As specified in the trial protocol | 5-Year |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse Events (Arrhythmias, Dialysis, Infection, Coronary Revascularization, Reintervention) | As specified in the trial protocol | 1-Year |
| Adverse Events (Arrhythmias, Dialysis, Infection, Coronary Revascularization, Reintervention) |
Not provided
- The target trial protocol will be used to develop an emulated trial protocol, which will give the best approximation of the trial protocol, given the limitations and constraints of the observational data. To mimic an actual trial population, the target trial population will be matched with individual patient data from a historical trial, targeting the same population.
Not provided
Not provided
Not provided
All Adult patients (18 years and above) with cardiovascular diseases (ICD10 I00-I99) treated in NHS hospitals in England.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gavin Murphy | University of Leicester | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, | Leicester | Leicestershire | LE3 9QP | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36350978 | Background | Pathak S, Lai FY, Miksza J, Petrie MC, Roman M, Murray S, Dearling J, Perera D, Murphy GJ. Surgical or percutaneous coronary revascularization for heart failure: an in silico model using routinely collected health data to emulate a clinical trial. Eur Heart J. 2023 Feb 1;44(5):351-364. doi: 10.1093/eurheartj/ehac670. | |
| 41638385 |
Not provided
Not provided
The data underlying this article were provided by National Health Service Digital under licence. Raw data may be shared with permission of National Health Service Digital.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
| OTHER |
| Newcastle University | OTHER |
| University of Bristol | OTHER |
Not provided
Not provided
Not provided
As specified in the trial protocol
| 3-Year |
| Adverse Events (Arrhythmias, Dialysis, Infection, Coronary Revascularization, Reintervention) | As specified in the trial protocol | 5-Year |
| Length of Hospital Stay | As specified in the trial protocol | 1-Year |
| Length of Hospital Stay | As specified in the trial protocol | 3-Year |
| Length of Hospital Stay | As specified in the trial protocol | 5-Year |
| Rehospitalisation | As specified in the trial protocol | 1-Year |
| Rehospitalisation | As specified in the trial protocol | 3-Year |
| Rehospitalisation | As specified in the trial protocol | 5-Year |
| Liao W, Rashid M, Brookes CL, Barber S, Turner RM, Gravel GM, Petrie MC, Lipsic E, Doenst T, Fremes S, Murphy GJ; High-Risk REVASC consortium. Study design for an emulated trial of a 2 arm, parallel, stratified, adaptive, RCT of CABG versus PCI in people requiring myocardial revascularization at high risk (High-Risk REVASC). Am Heart J. 2026 Jun;296:107368. doi: 10.1016/j.ahj.2026.107368. Epub 2026 Feb 2. |